After previously partnering on several biosimilar candidates in South Africa and emerging markets, Cipla has announced that its subsidiary, Cipla Gulf, is expanding its partnership with Alvogen sister company, Alvotech for the marketing and distribution of four biosimilars in Australia and New Zealand. The products include biosimilar versions of Eylea (aflibercept), Stelara (ustekimumab), Prolia/Xgeva (denosumab) and Simponi (golimumab).
“We are delighted to be taking this strategic step with Cipla,” said Anil Okay, Alvotech’s chief commercial officer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?